24 results about "Antibiotic sensitivity" patented technology

The invention discloses a preparation method and application of athlete-derived bifidobacterium probiotics for intestinal barrier repair, and relates to the technical field of biochemistry and microorganisms, and the preparation method comprises the steps of special bacteria source sampling, directional separation and purification, molecular biological identification, antibiotic sensitivity evaluation and injury repair verification. According to the preparation method and application of the sportsman-derived bifidobacterium probiotics for repairing the intestinal barrier, the sportsman intestinal flora is used as an exclusive bacterial source, and the unique metabolic elite attribute and stress adaptability of the sportsman intestinal flora are utilized to directionally screen and obtain a bifidobacterium strain adaptive to an extreme physiological stress environment; the bottleneck that conventional probiotics are only suitable for a common physiological environment and the survival rate and activity in a stress state are greatly reduced is broken through, high survival rate and metabolic activity can be kept in extreme environments such as exercise heat stress and the like, and accurate repair of intestinal barriers is realized through multiple mechanisms; meanwhile, an exclusive screening, identification and safety evaluation system is established, so that the safety and functional specificity of the strain are ensured.

1. Name of the product of this design: An electronic device having an operation display portion with a cascaded graphical user interface for constructing an antibiotic sensitivity test for microorganisms. 2. Purpose of this design product: This design product is used for an electronic device. 3. The key design features of this design product lie in the content requiring protection of the graphical user interface. 4. The picture or photo that best illustrates the key points of the design: main view. 5. Purpose of the graphical user interface: Overall purpose of the interface: For microorganisms in patient samples, clinicians use the interface to determine the drugs to which the microorganisms are susceptible and build cascades for candidate drug families. If the microorganisms show resistance to drugs in the previous layer, users can create multiple layers to prevent over-selection of antibiotics to prevent the microorganisms from developing resistance. The part of the interface is the operation display part of the cascade graphical user interface. The buttons on the left side of the interface allow users to add new cascades or view existing cascades; the two buttons in the upper right corner of the interface are used to delete and save cascades; users can enter the cascade name in the first rectangular box from the left at the top, click the second rectangular box to select the biological interpretation group, and click the third rectangular box to select the style type; users can edit the drug family name by clicking the pen icon in the middle of the interface, click the "Select drug" rectangular box to select a specific drug, and click the "+" rectangular box on the right to add a new drug cascade; click the "+" rectangular box at the bottom to add a new drug family. After the user clicks the rectangular box "Select drug" in the middle of the main view to select a drug, the interface changes to Change State Figure 1; after the user clicks the rectangular box "Select drug" in Change State Figure 1 to select a drug, the interface changes to Change State Figure 2; after the user clicks the rectangular box with a "+" symbol on the middle right of the interface in Change State Figure 2, the interface changes to Change State Figure 3; after the user clicks the rectangular box "Select drug" in the second column in the middle of Change State Figure 3 to select a drug, the interface changes to Change State Figure 4; after the user clicks the rectangular box with a "+" symbol on the middle right of Change State Figure 4, the interface changes to Change State Figure 5; after the user clicks the rectangular box with a "+" symbol at the bottom of the interface in Change State Figure 5 to add a new drug family, the interface changes to Change State Figure 6; after the user clicks the rectangular box "Select drug" in the second group of drug families in Change State Figure 6 to select a drug, the interface changes to Change State Figure 7; after the user clicks the rectangular box with a "+" symbol at the bottom of Change State Figure 7 to add a new drug family, the interface changes to Change State Figure 8. 6. Other situations that require explanation: The contents in the dotted part of the figure are not subject to protection.

The present invention relates to a novel peptide derived from Hirudo nipponia, which has antimicrobial activity, antibiofilm activity, antibiotic sensitivity–enhancing activity, and anti-inflammatory activity. With antimicrobial activity, antibiofilm activity, antibiotic sensitivity–enhancing activity, and anti-inflammatory activity, the novel peptide derived from Hirudo nipponia according to the present invention can be advantageously applied as a material for various purposes in the pharmaceutical field, food field, cosmetic field, and agriculture and livestock industries. In addition, the novel antimicrobial peptide derived from Hirudo nipponia according to the present invention increases the sensitivity of antibiotics to multidrug-resistant bacteria, thereby markedly enhancing antimicrobial activity against multidrug-resistant bacteria when used in combination with antibiotics. Accordingly, a composition of the present invention comprising the peptide as an active ingredient can be advantageously used as a pharmaceutical composition for enhancing antibiotic sensitivity. In particular, the novel peptide of the present invention has very low hemolytic activity and cytotoxicity, and thus is safe for the human body. Moreover, the novel peptide of the present invention not only has excellent activity even under a high salt concentration, but also maintains activity even in a serum environment, thereby having high stability when applied in vivo.

The utility model relates to the technical field of drug sensitive paper sheet distributors, and particularly discloses a distributor facilitating use of drug sensitive paper sheets in a laboratory, which comprises a bottom support, a shell and a material pushing assembly, a supporting plate with inner and outer layers of circumferential discharging holes is arranged on the inner side of the bottom support, the shell is connected with the bottom support through a rotary limiting assembly, and the inner and outer layers of circumferential medicine tube grooves and the discharging holes are arranged in a staggered mode in the radial direction. The pushing assembly is composed of a stand column, a base, a pressing rod, a push rod, a tension spring and an ejector pin, the pressing rod drives the push rod to laterally move through a first inclined guide face, and the ejector pin completes the ejection action of the medicine sensitive paper on the lowermost layer of the medicine tube under the reset action of the tension spring. The paper storage capacity is multiplied through the design of inner and outer double-layer medicine tube grooves, and the collaborative operation requirement of multiple types of paper sheets is met; shell rotation positioning is matched with trumpet-shaped discharging hole guiding, and it is guaranteed that the paper sheets accurately fall into circumferential equidistant positions of the culture dish.

The invention relates to a rapid antibiotic sensitivity detection and identification method, and the identification method can carry out antibiotic sensitivity detection and identification detection in a single process, and rapidly provide antibiotic information suitable for microorganisms. The invention provides a rapid antibiotic sensitivity detection and identification method which comprises the following steps: (a) transferring a sample extracted from a patient to a first reaction space in which a sample separation device exists; (b) capturing pathogens in a sample from a patient by a separation device within the first reaction space to separate and concentrate them; and (c) performing the identification of said pathogens or the detection of antibiotic sensitivity.

The invention relates to the field of food, in particular to probiotic characteristics of lactobacillus salivarius JCF5 and a method for preparing Jersey yogurt through synergistic fermentation of the lactobacillus salivarius JCF5. The strain provided by the invention is named as Lactobacillus salivarius JCF5, and the Latin is Ligillactobacillussavarius. The invention further discloses a preparation method of the strain. The strain provided by the invention has the advantages that the strain is named as Lactobacillus salivarius JCF5; the strain is obtained by randomly selecting six newly-born Jersey and six Jersey-and-cattle hybrid calves with good health conditions from a pasture in Heilongjiang province, collecting fetal manure of the Jersey and six Jersey-and-cattle hybrid calves after the Jersey and cattle hybrid calves are born, and separating manure samples after the Jersey and cattle hybrid calves eat colostrum. The water-holding capacity and whey precipitation rate of the Jersey yoghourt can be remarkably improved, and the viscosity of the Jersey yoghourt can be increased. In addition, the strain has better acid resistance, cholate resistance and simulated gastrointestinal fluid resistance, does not show hemolysis capacity and gelatinase activity, has stronger antibacterial capacity and antibiotic sensitivity, and has the characteristics of probiotics. The application potential of the strain in fermenting the Jersey yogurt is fully explored, the quality of the Jersey yogurt is expected to be improved by changing the strain proportion of the leavening agent sold in the market, and a new leavening agent is provided for fermentation of the Jersey yogurt.

Lactiplantibacillus plantarum JN-7, a bacterial powder, a preparation method, a probiotic composition and the use thereof. According to the present application, a new strain of Lactiplantibacillus plantarum named Lactiplantibacillus plantarum JN-7 with the deposit number of CGMCC No. 30605 is obtained by means of screening. By means of basic characteristic analysis (growth curve, acid resistance, bile salt resistance, and gastrointestinal fluid resistance), safety evaluation (antibiotic sensitivity, hemolytic capacity, toxigenic capacity, and cytotoxicity), adhesion evaluation, anti-inflammatory effect evaluation, production performance evaluation (fermentation yield and lyophilization yield), and stability tests (an accelerated storage stability test) of this strain, it is found that Lactiplantibacillus plantarum JN-7 is a safe strain with an excellent production performance, high stability, and an anti-inflammatory efficacy. The bacterial powder produced therefrom can remain stable and active for a long time.

The invention discloses an application of a breast milk-derived plant lactobacillus in improving allergic diseases and regulating intestinal flora, and belongs to the technical field of microorganisms. The plant lactobacillus GDMCC No: 63060 disclosed by the invention is obtained by being separated from breast milk. The strain provided by the invention has excellent gastrointestinal fluid tolerance, mucin adhesion and antibiotic sensitivity, can inhibit various pathogenic bacteria, can generate indole derivatives, effectively inhibits eczema mouse dermatitis symptoms, inhibits Th2 type immunoreaction hyperpolarization, and induces regulatory T cells. Therefore, the lactobacillus plantarum FN029 has a huge application prospect in preparation of products for inhibiting enteropathogenic bacteria, improving allergic diseases, regulating intestinal flora or promoting digestion function.

Disclosed in the present invention are a Lactiplantibacillus plantarum strain JN9, a preparation, a probiotic composition and the use thereof. The present application finds a novel Lactiplantibacillus plantarum strain JN9 by means of screening, and the accession number thereof is: CCTCCNO: M20241647c. By means of analysis of basic characteristics of the strain (growth curve, acid tolerance, bile salt tolerance and gastrointestinal fluid tolerance), safety evaluation (antibiotics sensitivity, hemolysis capacity, toxin production capacity, cytotoxicity and bioamine production capacity), adhesion evaluation, GABA production evaluation, alcohol tolerance evaluation and acetaldehyde dehydrogenase production capability evaluation, said strain is found to be a safe strain, and exhibits GABA production performance, alcohol tolerance and acetaldehyde dehydrogenase activity

The present disclosure introduces an AI-based empirical antibiotic recommendation system (100) designed to analyse patient data and recommend antibiotic treatments. The system (100) integrates with user devices via REST APIs and ensures secure operation through HTTPS. Client modules collect and pre-process raw data, ensuring integrity and compatibility. The pre-processed data is sent to the server (104) and forwarded to an input module (112) for authentication and validation. A processing module (114) standardizes the data, while a prediction module (116) identifies probable organisms and their antibiotic sensitivities. A clinical pathway module (118) generates dosing guidelines, and a prediction response module (120) displays the top three organisms with associated probabilities and recommended antibiotics. The antibiotics are color-coded for safety, and a feedback mechanism allows continuous system refinement.

Compositions and methods of preventing, slowing the progression of, or targeting antibiotic tolerance and increasing antibiotic sensitivity in intracellular bacteria. Compositions and methods of reducing the production of reactive oxygen and nitrogen species in a subject and methods of reducing antibiotic-tolerant persister cells. Methods can further include administration of antibiotics.

The invention discloses a cotton bollworm source pediococcus acidilactici with gossypol degradation capability and application thereof, and belongs to the technical field of microorganisms, the cotton bollworm source pediococcus acidilactici with gossypol degradation capability is classified and named as JYM-1, the preservation unit is China Center for Type Culture Collection, the preservation number is CCTCCM2025009, and the preservation number is CCTCCM2025009. The 16SrDNA sequence of the cotton bollworm source pediococcus acidilactici is as shown in SEQ ID NO: 1. Probiotics capable of degrading gossypol are separated from intestinal tracts of cotton bollworms, the probiotic characteristics and safety of the probiotics are evaluated through tests of gossypol tolerance, gossypol detoxification capacity, antioxidant capacity, bacteriostatic activity, gastrointestinal stability, antibiotic sensitivity, non-hemolysis and the like, and the nutritional quality of the cottonseed meal can be remarkably improved by fermenting the cottonseed meal with the probiotics. The achievement of the invention provides a new method for improving the safety and nutritional value of the cottonseed meal as the feed, and is also beneficial to developing new probiotic resources and promoting the innovative development of the feed industry.

According to one aspect of the present invention, an electronic device for performing antibiotic sensitivity detection of a microorganism may comprise: a processor for: obtaining antibiotic data, the antibiotic data being data measured according to a change in an electrical characteristic of a target microorganism under antibiotic treatment; judging whether the antibiotic data is positive or negative, and inputting the positive control group data, the negative control group data and the antibiotic data of the target microorganism into a trained deep learning model, the deep learning model judges whether the antibiotic data is positive or negative according to the positive control group data, the negative control group data and the antibiotic data of the target microorganism; and identifying antibiotic sensitivity information of the target microorganisms according to different antibiotic types and concentrations by using the judgment result.

The invention relates to a bactericidal adjuvant, which comprises a preparation capable of knocking out, knocking down or silencing a coding gene of alanine dehydrogenase of bacteria, or a preparation capable of destroying the alanine dehydrogenase function of the bacteria. By knocking out the ald gene, the sensitivity of aeromonas veronii to antibiotics is remarkably improved, and a brand-new technical method is provided for treatment of drug-resistant bacteria.

Lactiplantibacillus plantarum JN-7, a bacterial powder, a preparation method, a probiotic composition and the use thereof. According to the present application, a new strain of Lactiplantibacillus plantarum named Lactiplantibacillus plantarum JN-7 with the deposit number of CGMCC No. 30605 is obtained by means of screening. By means of basic characteristic analysis (growth curve, acid resistance, bile salt resistance, and gastrointestinal fluid resistance), safety evaluation (antibiotic sensitivity, hemolytic capacity, toxigenic capacity, and cytotoxicity), adhesion evaluation, anti-inflammatory effect evaluation, production performance evaluation (fermentation yield and lyophilization yield), and stability tests (an accelerated storage stability test) of this strain, it is found that Lactiplantibacillus plantarum JN-7 is a safe strain with an excellent production performance, high stability, and an anti-inflammatory efficacy. The bacterial powder produced therefrom can remain stable and active for a long time.

The present disclosure relates to a microchamber device (1) for antibiotic sensitivity testing of bacterial cells (12) of a range of bacterial cell sizes, the microchamber device (1) being arranged on a substrate (40). The invention relates to a microchamber device (1) comprising a microchamber (11), a fluid inlet (14) and a fluid outlet (16) in fluid communication with the microchamber (11), and an integrated sensor (18) arranged in the microchamber (11), the sensor (18) being configured to monitor properties of bacterial cell activity in the microchamber (11) in real time and characterized in that the microchamber (11) comprises at least one trapping device (20), the trapping device (20) being configured to trap bacterial cells in the microchamber (11). And at least one sensor configured to capture at least one bacterial cell (12) in the microchamber (11). The present disclosure also relates to a test system (2) comprising at least one microchamber device (1) and a method for performing an antibiotic sensitivity test on bacterial cells (12).

The invention discloses a myxofactins compound derived from myxococcus as well as a preparation method and application of the myxofactins compound, and belongs to the technical field of biological medicines. The structure of the myxofactins compound derived from myxofactins provided by the invention is shown as a formula (I), a formula (II) or a formula (III). Formula (I). The myxofactins compound provided by the invention has no obvious cytotoxic activity, can be used as an antibiotic adjuvant, remarkably improves the sensitivity of gram-negative bacteria such as acinetobacter baumannii to antibiotics, and provides a new thought for solving the problem of multidrug resistance of gram-negative bacteria and improving the curative effect of existing antibiotics. The preparation method provided by the invention realizes high yield through a heterologous expression technology, has the advantages of mild culture conditions, simple and feasible culture medium preparation, short fermentation time and the like, and is convenient for large-scale production.

The application relates to a lactococcus lactis strain with functions of lowering blood fat, lowering blood sugar, lowering uric acid, resisting aging, resisting bacteria, resisting oxidation and lowering nitrite and application thereof, which is separated from Guizhou traditional fermented koji, has the abilities of lowering blood fat, lowering blood sugar and lowering uric acid; significantly prolongs the life of Caenorhabditis elegans, improves the exercise capacity and the mitochondrial membrane potential, but does not affect the reproductive capacity; has good gastrointestinal tolerance, acid tolerance and bile salt tolerance; has self-aggregation, co-aggregation and hydrophobicity and antibiotic sensitivity; has significant bacteriostatic and nitrite degradation abilities; has high DPPH, ABTS + scavenging capacity, reduces the contents of ROS and MDA in the body and improves the antioxidant enzyme activity. The strain not only integrates the functions of lowering blood fat, lowering blood sugar, lowering uric acid and resisting aging, but also has the abilities of resisting bacteria, resisting oxidation and degrading nitrite, and has a wide application prospect in the preparation of probiotic preparations or functional foods for assisting the regulation of metabolic syndrome and the delay of aging.

Disclosed is the use of copper ionophores for overcoming or inhibiting the development of resistance of a gram-positive bacterium to an antibiotic. More particularly, this disclosure relates to the use of a thiosemicarbazone, elesclomol or nitroxoline or a pharmaceutically acceptable salt or solvate thereof for conferring antibiotic sensitivity to a resistant gram-positive bacterium, inhibiting the development of resistance of a gram-positive bacterium to an antibiotic, increasing the susceptibility of a gram-positive bacterium to an antibiotic and / or treating or inhibiting the development of a gram-positive bacterial infection in a subject. Also provided is the use of a thiosemicarbazone, elesclomol or nitroxoline or a pharmaceutically acceptable salt or solvate thereof as an antibiotic adjuvant or potentiator.

The invention discloses a compound for recovering sensitivity of beta-lactam antibiotics, a composition and application, and belongs to the field of chemical medicines. The invention provides a boric acid compound with a brand new structure as shown in a formula (I) and a pharmaceutically acceptable salt thereof, on one hand, the boric acid compound has better metabolic stability and biological activity, and the administration time interval is expanded; on the other hand, the method can be better used for interfering a beta-lactam antibiotic reaction pathway, so that MSSA and MRSA bacteria have better sensitivity to lactam drugs.

The application discloses Lactobacillus plantarum S-03 with high folate yield and excellent gastrointestinal tolerance, and application thereof, and is preserved in the China General Microbiological Culture Collection Center with a strain preservation number of CGMCC No. 37968. The application aims to provide Lactobacillus plantarum with high folate yield and excellent gastrointestinal tolerance and application thereof, which can not only yield high folate, but also has good gastrointestinal tolerance, hydrophobicity, antibiotic sensitivity and hemolytic activity-free lactic acid bacteria, so that the lactic acid bacteria can stably play a function in the intestinal tract for a long time.

The present invention belongs to the field of agricultural microbial technology and discloses a food-grade strain of Pediococcus pentosaceus L1 that efficiently reduces sodium selenite to produce nano-selenium and its application. The deposit number of Pediococcus pentosaceus L1 is CCTCC NO: M 2024628. The strain has good acid production capacity, strong acid tolerance, bile salt tolerance, simulated gastrointestinal survival rate and antibiotic sensitivity, etc., and has a good animal experimental basis. At the same time, L1 also has good selenium reduction ability and can produce small-sized biological nano-selenium particles. As a facultative anaerobic selenium-rich nano-selenium-producing probiotic, L1 has good growth characteristics and the ability to reduce sodium selenite to produce nano-selenium under both aerobic and anaerobic conditions, and has a good industrial production fermentation basis. Its probiotic properties and the anti-inflammatory, antioxidant and selenium-supplementing properties of biological nano-selenium have good application prospects.

The invention relates to enterococcus lactis W3F and application thereof.The enterococcus lactis W3F capable of reducing blood pressure, blood sugar and / or uric acid is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.32832. The strain has good exopolysaccharide production capacity, good safety, antibiotic sensitivity and relatively strong gastrointestinal tract tolerance; the strain or the fermentation product thereof has an inhibiting effect on the activity of xanthine oxidase, alpha-amylase, alpha-glucosidase and angiotensin converting enzyme, and can be used for preparing medicines, functional foods or functional health-care products for reducing blood pressure, blood sugar and / or uric acid. The enterococcus lactis W3F disclosed by the invention is suitable for patients with hyperglycemia, hypertension and hyperuricemia at the same time, and in addition, a fermented food prepared by fermenting the enterococcus lactis W3F also has the effects of reducing blood pressure, reducing blood sugar and / or reducing uric acid, and can be used as a functional food or a functional health-care product.

The application discloses a pathogen identification and drug resistance prediction method and system based on metagenomic sequencing, and the method comprises the following steps: S1, obtaining original data of clinical samples through metagenomic sequencing and preprocessing; S2, comparing the preprocessed sequencing data with a pathogenic microorganism reference database to identify the pathogen types and relative abundance of the clinical samples; S3, comparing the preprocessed data with a drug resistance gene database to identify the drug resistance genes and virulence factors carried by the pathogen; S4, taking at least one of the pathogen types, relative abundance, drug resistance genes and patient clinical information as input characteristics, and using a machine learning model to predict the drug resistance phenotype of the pathogen to specific antibiotics; and S5, integrating the pathogen types and abundance, drug resistance gene spectrum and predicted antibiotic sensitivity spectrum to generate and output a structured clinical report containing treatment suggestions; the application realizes pathogen identification, drug resistance phenotype prediction and treatment suggestion generation through metagenomic sequencing combined with a machine learning model.